Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02479945 · ClinicalTrials.gov registry record · NA

Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer

A NA study of Prostate Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT02479945 is a NA study of Prostate Cancer that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02479945, a NA study of Prostate Cancer, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The investigators will compare tumor marker levels, including PSA, in samples taken from a peripheral upper limb vein and the internal iliac veins. These will be collected from patients who are scheduled for prostatectomy as part of their standard of care for prostate cancer. A selective internal iliac vein sampling procedure will be performed in Interventional Radiology. Venous samples will be correlated with prostatectomy specimens. The aim is to predict the side of the prostate containing tumor.

Conditions Studied

Interventions

  • OTHER Obtaining biospecimen

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2012-01
Est. Completion 2013-04-25
Phase NA

What the Registry Record Tells You About NCT02479945

The ClinicalTrials.gov registry entry for NCT02479945 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Obtaining biospecimen is the first listed.

NCT02479945 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02479945 about?

NCT02479945 is a clinical study titled "Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer". The investigators will compare tumor marker levels, including PSA, in samples taken from a peripheral upper limb vein and the internal iliac veins. These will be collected from patients who are scheduled for prostatectomy as part of their standard of care for prostate cancer. A selective internal il...

What is the current status of trial NCT02479945?

This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2012-01. Estimated completion is 2013-04-25.

What conditions does trial NCT02479945 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT02479945?

The interventions under investigation include: Obtaining biospecimen (OTHER).

Who is sponsoring clinical trial NCT02479945?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02479945 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.